The Value of Early Commercialization

As the pharmaceutical industry contends with reduced periods of exclusivity, aggressive generic competition, increased regulation and the prevalence of managed care, many companies are turning to early commercialization to boost the return on investment of research & development; according to a new global study by Capgemini. The 6th Edition of Capgemini’s Vision & Reality Study, From Market to Discovery and Back: The Value of Early Commercialization is based on input from 200 leading industry executives from the pharmaceutical and biotech sectors across Europe, North America, and Asia.